# Neoplasm, Residual trials, no drug phase: 21 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with no drug phase for Neoplasm, Residual that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Neoplasm, Residual trials with no drug phase: 21 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/not-applicable/neoplasm-residual

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 21
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07924046 | Diagnostic Performance of Multiparametric Magnetic Resonance Imaging After Transurethral Resection of Bladder Tumour for Prediction of... | University of Lausanne Hospitals | Not applicable | Not yet recruiting | Urinary Bladder Cancer, NMIBC, TURBT, Vi-Rads | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07924046) |
| October 26, 2026 | NCT07895459 | MRD Monitoring in Colorectal Cancer Using ctDNA | Masaryk Memorial Cancer Institute | Not applicable | Recruiting | Colorectal Neoplasms, Colorectal Cancer (Diagnosis), Minimal Residual Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895459) |
| October 26, 2026 | NCT07894458 | MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer | Peking University People's Hospital | Not applicable | Recruiting | Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894458) |
| October 14, 2026 | NCT07873086 | MRD-Guided Aumolertinib-Based Adjuvant Therapy for Resected EGFR-Mutant NSCLC | Peking University People's Hospital | Not applicable | Not yet recruiting | Non-Small Cell Lung Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873086) |
| June 22, 2026 | NCT07660627 | Determining Minimal Residual Disease Using ctDNA Deep Sequencing | Masaryk Memorial Cancer Institute | Not applicable | Recruiting | Esophageal Adenocarcinoma, Gastric Cancer, Pancreatic Cancer | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660627) |
| March 2, 2026 | NCT07443592 | Treatment for Ph-negative ALL for Adults up to 65 Years | PETHEMA Foundation | Not applicable | Not yet recruiting | Acute Lymphoblastic Leukemia | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07443592) |
| February 17, 2026 | NCT07413146 | Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized... | Sun Yat-sen University | Not applicable | Not yet recruiting | Minimal Residual Disease, Immunoscore, Neoadjuvant Chemotherapy, Colon Cancer (Stage II &Amp; III) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07413146) |
| January 20, 2026 | NCT07350824 | Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC | Tongji Hospital | Not applicable | Not yet recruiting | HCC, Minimal Residual Disease, Recurrence | 276 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07350824) |
| September 17, 2025 | NCT07178847 | cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas | Centre Jean Perrin | Not applicable | Recruiting | Locally Advanced Head and Neck Carcinoma | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07178847) |
| August 20, 2025 | NCT07131059 | MRD-positive AML Clinical Study | Institute of Hematology & Blood Diseases Hospital, China | Not applicable | Recruiting | AML, Adult | 537 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07131059) |
| June 17, 2025 | NCT07025785 | Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer | UNC Lineberger Comprehensive Cancer Center | Not applicable | Recruiting | Breast Cancer, Lymph Node Metastasis | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07025785) |
| June 4, 2025 | NCT07003737 | Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation | First Affiliated Hospital of Zhejiang University | Not applicable | Recruiting | Acute Lymphoblastic Leukemia, B-precursor | 114 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07003737) |
| April 16, 2025 | NCT06930807 | Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer | Peking University People's Hospital | Not applicable | Recruiting | Non-small Cell Lung Cancer, Minimal Residual Disease, Adaptive Treatment | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06930807) |
| March 20, 2025 | NCT06885476 | Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Not applicable | Recruiting | Acute Myeloid Leukemia, Minimal Residual Disease, Natural Killer Cell | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06885476) |
| January 8, 2025 | NCT06763302 | NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL | The Children's Hospital of Zhejiang University School of Medicine | Not applicable | Not yet recruiting | B Cell Precursor Acute Lymphoblastic Leukemia, Pediatric, Minimal Residual Disease, Next Generation Sequencing (NGS) | 1,220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06763302) |
| November 20, 2024 | NCT06697483 | Risk Stratification and MRD-driven Maintenance for MM After ASCT | Peking University People's Hospital | Not applicable | Recruiting | Multiple Myeloma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06697483) |
| November 18, 2024 | NCT06693830 | ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL | Sponsor not shown (see the record) | Not applicable | Recruiting | Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06693830) |
| March 8, 2024 | NCT06301425 | MRD Response-adapted Allo-HSCT for Adverse-risk AML | Peking University People's Hospital | Not applicable | Recruiting | Acute Myeloid Leukemia | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06301425) |
| October 19, 2023 | NCT06090786 | Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax | Gruppo Italiano Malattie EMatologiche dell'Adulto | Not applicable | Not yet recruiting | AML, Adult, Minimal Residual Disease | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06090786) |
| October 4, 2023 | NCT06066905 | A Study of Chidamide With AZA in MRD Positive AML After Transplant | Guangdong Provincial People's Hospital | Not applicable | Recruiting | AML, Adult, Minimal Residual Disease | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06066905) |
| November 27, 2019 | NCT04179929 | Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults | PETHEMA Foundation | Not applicable | Recruiting | Acute Lymphoblastic Leukemia | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04179929) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Peking University People's Hospital | 5 |
| Masaryk Memorial Cancer Institute | 2 |
| PETHEMA Foundation | 2 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 1 |
| Centre Jean Perrin | 1 |
| Tongji Hospital | 1 |
| Guangdong Provincial People's Hospital | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Sun Yat-sen University | 1 |
| The Children's Hospital of Zhejiang University School of Medicine | 1 |
| University of Lausanne Hospitals | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 9 |
| Czechia | 2 |
| Spain | 2 |
| United States | 2 |
| France | 1 |
| Italy | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Process servers in the United States](https://specstream.ai/data/businesses/process-servers/united-states)
- [Business brokers in the United States](https://specstream.ai/data/businesses/business-brokers/united-states)
- [Malaysian restaurants in the United States](https://specstream.ai/data/businesses/malaysian-restaurants/united-states)
- [Wineries in the United States](https://specstream.ai/data/businesses/wineries/united-states)
- [Garage door companies in the United States](https://specstream.ai/data/businesses/garage-door-companies/united-states)
- [Shipping and delivery companies in the United States](https://specstream.ai/data/businesses/shipping-and-delivery-companies/united-states)
